Sentynl holds an exclusive U.S. commercialization option for AATD-LD, while securing global manufacturing rights; Mereo retains commercial rights outside the U.S. and leads Phase III execution.
We have been telling ourselves a story about pharma communications for the past 20 years. The story goes like this: Global ...
President Trump signs an executive order shrinking the recommended childhood vaccine schedule from 18 diseases to 11, and calls for the MMR shot to be split into three separate injections. President ...
Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...
In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...
Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...
Platelet count remains central for bleeding risk assessment, yet discordance with fatigue, cognitive symptoms, anxiety, and productivity loss necessitates broader multidimensional disease-control ...
In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...
Consideration includes $820 million upfront and up to $500 million in approval and sales milestones, with financing expected from cash on hand and existing credit facilities. ABS-1230 is a ...
FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...
Even products with a competitive advantage underperform three-year consensus targets 29% of the time; product superiority ...
Commercial Evidence aggregates compliant signals from in-person and digital engagement to reveal “why/why not” drivers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results